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cell viability and prevent apoptosis. The protective effects of adipo-
nectin against Ang II-induced vascular endothelial damage are
dependent on the binding of adiponectin to its cell surface receptor1.
Importantly, adiponectin treatment was found to modulate the
apoptotic pathway by reducing the expression of LOX-1, upregulating
both cIAP-1 and the ratio of Bcl-2/Bax, and activating AMPK by APPL1.
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BACKGROUND Atherosclerosis is a progressive inﬂammatory disease
which can lead to sudden cardiac events by plaque rupture and sub-
sequent thrombosis. FXa not only occupies a crucial position in the
coagulation cascade responsible for thrombin generation, but also has
potential effects on inﬂammation. Targeting FXa is attracting more
and more attention as a potential therapeutic strategy. Hence, we
assess the effects of fondaparinux, the speciﬁc indirect FXa inhibitor,
on the development and stability of atherosclerotic lesions in apoli-
poprotein E-deﬁcient mice.
METHODS Male ApoE–/– mice were placed on a lard-containing diet
comprising 21% lard and 0.15% added cholesterol at 6 weeks of age. At
16 weeks of age, all mice were subjected to 4 weeks of chronic stress
by placing them in a cage containing 1 cm of iced water for 1 hour per
day, 5 days per week. At 20 weeks of age, mice were divided into two
groups (12 mice per group): disease control group and fondaparinux
treatment group. Fondaparinux (GlaxoSmithKlin Pharma Co., LTD.,
Middlesex, UK) was intraperitoneally administered at a dose of 5 mg/
kg/day according to body weight from week 20 to 24. In the control
group, the same volume of 0.9% saline was intraperitoneally injected
with the same intervals.
RESULTS Fondaparinux did not remarkably decrease the total lesion
area, maximum lesion thickness or percentage of stenosis, it did not
decrease the progression of atherosclerosis development in apolipo-
protein E-deﬁcient mice signiﬁcantly, but increased the thickness of
ﬁbrous cap (56.78  6.18 mm versus 42.35  2.62 mm of the control
group, p¼0.049) and decreased the ratio of necrotic core (34.8 
0.91% versus 41.32  1.44% of the control group, p¼0.001) signiﬁ-
cantly (Figure 1, 2). Moreover, Fondaparinux reduced the macro-
phagocyte recruitment (3.89  0.41 versus 5.24  0.35 of the control
group, p¼0.017) and the mRNA expression of inﬂammatory mediators
(p<0.05) signiﬁcantly, such as IL-6, MCP-1, IFN-g, TNF-a and Erg-1.CONCLUSION Fondaparinux can promote the stability of atherosclerotic
lesions in apolipoprotein E–deﬁcient mice, possibly via its anti-inﬂamma-
tory mechanism. Targeting FXamay be a potential therapeutic strategy for
patients with established atherosclerotic disease.
